CA2325087A1 - Glucosides de sterol dans une maladie - Google Patents

Glucosides de sterol dans une maladie Download PDF

Info

Publication number
CA2325087A1
CA2325087A1 CA002325087A CA2325087A CA2325087A1 CA 2325087 A1 CA2325087 A1 CA 2325087A1 CA 002325087 A CA002325087 A CA 002325087A CA 2325087 A CA2325087 A CA 2325087A CA 2325087 A1 CA2325087 A1 CA 2325087A1
Authority
CA
Canada
Prior art keywords
glutamate
cycad
mso
gsh
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002325087A
Other languages
English (en)
Inventor
Christopher A. Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to CA002325087A priority Critical patent/CA2325087A1/fr
Priority to DK01992897.7T priority patent/DK1334368T5/en
Priority to AU2002223317A priority patent/AU2002223317A1/en
Priority to CA2464232A priority patent/CA2464232C/fr
Priority to EP01992897.7A priority patent/EP1334368B1/fr
Priority to PCT/CA2001/001567 priority patent/WO2002037122A2/fr
Priority to US10/415,710 priority patent/US20040048810A1/en
Publication of CA2325087A1 publication Critical patent/CA2325087A1/fr
Priority to US11/477,730 priority patent/US8148336B2/en
Priority to US13/435,825 priority patent/US8497123B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002325087A 2000-11-03 2000-11-03 Glucosides de sterol dans une maladie Abandoned CA2325087A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002325087A CA2325087A1 (fr) 2000-11-03 2000-11-03 Glucosides de sterol dans une maladie
DK01992897.7T DK1334368T5 (en) 2000-11-03 2001-11-02 Sterolglykosidtoksiner
AU2002223317A AU2002223317A1 (en) 2000-11-03 2001-11-02 Sterol glucoside toxins
CA2464232A CA2464232C (fr) 2000-11-03 2001-11-02 Toxines de sterol glucoside
EP01992897.7A EP1334368B1 (fr) 2000-11-03 2001-11-02 Toxines de sterol glucoside
PCT/CA2001/001567 WO2002037122A2 (fr) 2000-11-03 2001-11-02 Toxines de sterol glucoside
US10/415,710 US20040048810A1 (en) 2000-11-03 2001-11-02 Sterol glucoside toxins
US11/477,730 US8148336B2 (en) 2000-11-03 2006-06-29 Sterol glucoside toxins
US13/435,825 US8497123B2 (en) 2000-11-03 2012-03-30 Sterol glucoside toxins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002325087A CA2325087A1 (fr) 2000-11-03 2000-11-03 Glucosides de sterol dans une maladie

Publications (1)

Publication Number Publication Date
CA2325087A1 true CA2325087A1 (fr) 2002-05-03

Family

ID=4167548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325087A Abandoned CA2325087A1 (fr) 2000-11-03 2000-11-03 Glucosides de sterol dans une maladie

Country Status (1)

Country Link
CA (1) CA2325087A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048710A1 (fr) * 2008-10-31 2010-05-06 Neurodyn, Inc. Glycosides de stérol neurotoxiques
CN109122831A (zh) * 2018-07-05 2019-01-04 中国热带农业科学院农产品加工研究所 一种番荔枝鲜果保鲜剂及其制备方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048710A1 (fr) * 2008-10-31 2010-05-06 Neurodyn, Inc. Glycosides de stérol neurotoxiques
CN102272321A (zh) * 2008-10-31 2011-12-07 神经动力公司 神经毒性甾醇糖苷
US9573972B2 (en) 2008-10-31 2017-02-21 Neurodyn, Inc. Nurotoxic sterol glycosides
CN109122831A (zh) * 2018-07-05 2019-01-04 中国热带农业科学院农产品加工研究所 一种番荔枝鲜果保鲜剂及其制备方法

Similar Documents

Publication Publication Date Title
US8148336B2 (en) Sterol glucoside toxins
Khabazian et al. Isolation of various forms of sterol β‐d‐glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS‐parkinsonism dementia complex
Rosemberg et al. Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain
Wilson et al. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour
Bloomer Effect of exercise on oxidative stress biomarkers
Czerniczyniec et al. Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction
Yadav et al. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model
Kucukatay et al. Effect of sulfur dioxide on active and passive avoidance in experimental diabetes mellitus: relation to oxidant stress and antioxidant enzymes
Cunningham et al. HIGH INTENSITY SPRINT TRAINING REDUCES LIPID PEROXIDATION IN FAST-TWITCH SKELETAL MUSCLE.
KR20080066802A (ko) 간 건강 개선을 위한 식물성 제형물
Marshall et al. The neuronal toxicity of sulfite plus peroxynitrite is enhancede by glutathione depletion: implications for Parkinson’s disease
Moothoo-Padayachie et al. Germination associated ROS production and glutathione redox capacity in two recalcitrant-seeded species differing in seed longevity
Shapiro et al. Characterization of demethylation of methylmercury in cultured astrocytes
Olofsson et al. Glucose-induced cataract in CuZn-SOD null lenses: an effect of nitric oxide?
Almeida et al. Postnatal development of the complexes of the electron transport chain in synaptic mitochondria from rat brain
Yargicoglu et al. The effect of sulfur dioxide inhalation on active avoidance learning, antioxidant status and lipid peroxidation during aging
CA2325087A1 (fr) Glucosides de sterol dans une maladie
Arakawa et al. N-Acetylcysteine and ebselen but not nifedipine protected cerebellar granule neurons against 4-hydroxynonenal-induced neuronal death
Rawling et al. Lung poly (ADP-ribose) and NAD+ concentrations during hyperoxia and niacin deficiency in the Fischer-344 rat
Horemans et al. Transport of ascorbate into protoplasts of Nicotiana tabacum Bright Yellow-2 cell line
Pepe The effects of gender and exercise on malondialdehyde, nitric oxide and total glutathione levels in rat liver
CA2342085A1 (fr) Sterol-glucosides toxiques
Cavallini et al. Effects of chemical ischemia in cerebral córtex slices: focus on nitric oxide
CA2464232C (fr) Toxines de sterol glucoside
Unger et al. Acoustic startle response is disrupted in iron-deficient rats

Legal Events

Date Code Title Description
FZDE Dead